Browse News
Filter News
Found 809,064 articles
-
Policy changes by health insurance companies will likely determine which Humira biosimilars rise to the top.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair
4/24/2024
Harness Therapeutics, a biotechnology company focused on protein upregulation to develop next generation therapeutics for neurodegenerative diseases, announced the appointment of Ms. Meenu Chhabra Karson as Chair of its Board of Directors.
-
BioInvent International AB: Interim Report January-March 2024
4/24/2024
During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023.
-
Xaira Therapeutics Launches to Deliver Transformative Medicines by Advancing and Harnessing AI for Drug Discovery and Development
4/24/2024
Xaira Therapeutics launched on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies.
-
Spago Nanomedical Reports Favorable Data in Breast Cancer Model with Tumorad
4/24/2024
Spago Nanomedical AB announced data from a non-clinical study exploring 177Lu-SN201 in a model for triple-negative breast cancer.
-
Angle PLC Announces New Commercial Agreement with AstraZeneca
4/24/2024
ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumour cell solutions for use in research, drug development and clinical oncology has signed a supplier agreement with the global biopharmaceutical company, AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE's existing DNA damage response assay for the detection of micronuclei in CTCs as a measure of DDR.
-
AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting
4/24/2024
AAVantgarde Bio announces the publication of an abstract submitted to The Association for Research in Vision and Ophthalmology Annual Meeting, to be held May 5-9 in Seattle.
-
Evotec Presents Fiscal Year 2023 Results and Announces Priority Reset to Focus on Profitable Growth
4/24/2024
Evotec SE reported financial results and corporate updates for the fiscal year ended 31 December 2023 and announced a priority reset to optimise its business to meet evolving market demand and focus on profitable growth in 2024 and beyond.
-
Kuros Reports Corporate Highlights as of Q1 2024 Including Increase in Direct MagnetOsTM Sales
4/24/2024
Kuros Biosciences, a leader in advanced bone healing technologies, announced its financial performance for the first quarter of 2024.
-
Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agent
4/24/2024
Nicox SA informs its shareholders that the Ordinary and Extraordinary General Meeting, having been unable to deliberate on April 10, 2024 as the quorum required by law has not been reached, will be held, on second convening, on Monday May 6, 2024 at 2:30 p.m., at the offices of BuroClub - Drakkar 2 Bâtiment D - 2405 route des Dolines - 06560 Valbonne Sophia Antipolis.
-
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
4/24/2024
Ipsen, a global specialty-care biopharmaceutical company, presents its sales for the first quarter of 2024.
-
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
4/24/2024
Pharming Group N.V. is pleased to announce its recognition as an Industry Innovator by the National Organization for Rare Disorders at the Rare Impact Awards on June 8, 2024.
-
GenScript Singapore's Open Day Reveals Pioneering AI Capabilities in Recombinant Protein Production and Drug Discovery
4/24/2024
GenScript, a global leader in life sciences and biotechnology, successfully hosted an Open Day event at its Singapore facility on the 16th of April, welcoming more than 50 representatives from Singapore.
-
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
4/24/2024
Centessa Pharmaceuticals plc announced the pricing of an underwritten public offering of 10,810,810 American Depositary Shares, each representing one ordinary share, at a price to the public of $9.25 per ADS.
-
Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab)
4/24/2024
Hanmi Pharmaceutical announces Clinical Trial Collaboration with MSD to evaluate 'BH3120' in combination with KEYTRUDA in phase 1 clinical trial in patients with progressive or metastatic solid tumors
-
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
4/24/2024
CSL Vifor and Travere Therapeutics, Inc., announced that the European Commission has granted conditional marketing authorization for FILSPARI for the treatment of adults with primary IgAN with a urine protein excretion ≥1.0 g/day.
-
Samsung Biologics Reports First Quarter 2024 Financial Results
4/24/2024
Samsung Biologics, a global contract development and manufacturing organization, announced financial results for the first quarter of fiscal year 2024.
-
The Swiss drugmaker raised its full-year guidance Tuesday projecting net sales to grow in the high-single to low double-digit range while reporting better-than-expected first-quarter results.
-
CEO Hervé Hoppenot said Tuesday on an investor call that Escient Pharmaceuticals’ two lead assets “address large populations with a clear medical need” with a potential multibillion-dollar market opportunity.